{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:17:54Z","timestamp":1793913474063,"version":"4.8.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"Importance<\/jats:title>Case reports and small retrospective studies have suggested that there is an increased risk of postoperative euglycemic ketoacidosis (eKA) and acute kidney injury (AKI) among patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively. However, there has not been a representative assessment of the risks of these agents among patients undergoing surgery.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the risk of postoperative eKA, AKI, and mortality within 30 days after surgery among preoperative long-term SGLT2i users compared with nonusers.<\/jats:p><\/jats:sec>Design, Settings, and Participants<\/jats:title>This is a multicenter, propensity-matched, retrospective case-control study from the Veterans Affairs Health Care System (VAHCS) National Registry performed from January 1, 2014, to December 31, 2022. Adult patients using SGLT2i preoperatively who underwent inpatient surgical procedures were compared with a 1:5 matched control group using propensity score matching, including the patient\u2019s demographic characteristics, comorbidities, and surgical characteristics. Data analysis was performed from June 2023 to August 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Long-term use of SGLT2i, defined as having more than 3 fills of outpatient prescription or less than a 180-day gap of the last fill according to the VAHCS pharmacy registries.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the rate of postoperative eKA among SGLT2i users vs control patients. Secondary outcomes included postoperative AKI and 30-day mortality after surgery.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 462\u202f968 patients undergoing surgery, 7448 SGLT2i users (mean [SD] age, 67.7 [8.1] years; 7204 [96.7%] male) and 455\u202f520 nonusers (mean [SD] age, 65.8 [11.0] years; 424\u202f785 [93.3%] male) were identified. After propensity score matching, 7439 patients were identified as SGLT2i users and compared with 33\u202f489 control patients. SGLT2i use was associated with an increased risk of eKA (odds ratio [OR], 1.11; 95% CI, 1.05-1.17) but reduced risks of perioperative AKI (OR, 0.69; 95% CI, 0.62-0.78) and 30-day mortality (OR, 0.70; 95% CI, 0.55-0.88). The mortality rate 30 days after surgery was 1.1% among SGLT2i users vs 1.6% among control patients. The median hospital length of stay among the patients presenting with eKA increased by 3 days (median [IQR], 6 [3-10] days for those with eKA vs 3 [2-6] days for those without eKA).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Patients treated with SGLT2i had a small but significantly higher risk of postoperative eKA but lower risks of postoperative AKI and 30-day mortality.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamasurg.2025.0940","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:30:18Z","timestamp":1746055818000},"page":"681","source":"Crossref","is-referenced-by-count":44,"title":["Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users"],"prefix":"10.1001","volume":"160","author":[{"given":"Roberta Teixeira","family":"Tallarico","sequence":"first","affiliation":[{"name":"Department of Anesthesia and Perioperative Care, University of California, San Francisco"},{"name":"Department of Anesthesiology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bocheng","family":"Jing","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, University of California, San Francisco"},{"name":"Northern California Institute for Research and Education, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Lu","sequence":"additional","affiliation":[{"name":"Northern California Institute for Research and Education, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta Amy","family":"Chawla","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Luo","sequence":"additional","affiliation":[{"name":"Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Badathala","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine L.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Care, University of California, San Francisco"},{"name":"Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur W.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Care, University of California, San Francisco"},{"name":"Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Care, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"soi250016r1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature.","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"5","key":"soi250016r2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 inhibitors: a narrative review.","volume":"14","author":"Morace","year":"2024","journal-title":"Metabolites"},{"issue":"1","key":"soi250016r3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/ACO.0000000000000674","article-title":"Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications.","volume":"32","author":"Bardia","year":"2019","journal-title":"Curr Opin Anaesthesiol"},{"issue":"21","key":"soi250016r4","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease.","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"soi250016r5","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1053\/j.jvca.2022.02.019","article-title":"SGLT-2 inhibitors: proliferating indications and perioperative pitfalls.","volume":"36","author":"Madhok","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"soi250016r6","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221081601","article-title":"Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future.","volume":"13","author":"Mallik","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"soi250016r7","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"soi250016r8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"soi250016r9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update.","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"soi250016r10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"soi250016r11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect.","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"soi250016r12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs.","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"soi250016r13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis.","volume":"11","author":"Dutta","year":"2022","journal-title":"J Family Med Prim Care"},{"issue":"1","key":"soi250016r14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12882-020-01930-6","article-title":"Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.","volume":"21","author":"Sampani","year":"2020","journal-title":"BMC Nephrol"},{"issue":"1","key":"soi250016r15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12902-022-01126-z","article-title":"The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: a retrospective cohort study.","volume":"22","author":"Iwasaki","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"9","key":"soi250016r16","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors\u2014lessons from a case series and strategies to decrease incidence.","volume":"28","author":"Mehta","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"soi250016r17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00134-024-07704-0","article-title":"How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient?","volume":"51","author":"Garcia","year":"2025","journal-title":"Intensive Care Med"},{"issue":"2","key":"soi250016r18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0310057X1804600212","article-title":"Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature.","volume":"46","author":"Chacko","year":"2018","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"soi250016r19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12630-017-1018-6","article-title":"Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery.","volume":"65","author":"Lau","year":"2018","journal-title":"Can J Anaesth"},{"issue":"7","key":"soi250016r20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1213\/XAA.0000000000000888","article-title":"Metabolic acidosis in postsurgical patient on canagliflozin and metformin: a case report.","volume":"12","author":"Darwish","year":"2019","journal-title":"A A Pract"},{"key":"soi250016r21","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.929773","article-title":"Life-threatening complications related to delayed diagnosis of euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: a report of 2 cases.","volume":"22","author":"Goto","year":"2021","journal-title":"Am J Case Rep"},{"key":"soi250016r22","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.828649","article-title":"New diabetic medication sodium-glucose cotransporter-2 inhibitors can induce euglycemic ketoacidosis and mimic surgical diseases: a case report and review of literature.","volume":"9","author":"Kietaibl","year":"2022","journal-title":"Front Surg"},{"issue":"12","key":"soi250016r23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1177\/0003134820940286","article-title":"euglycemic diabetic ketoacidosis associated with use of SGLT2 inhibitor after laparoscopic Roux-en-Y gastric bypass.","volume":"87","author":"Yared","year":"2021","journal-title":"Am Surg"},{"issue":"2","key":"soi250016r24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report.","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med"},{"issue":"3","key":"soi250016r26","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000001570","article-title":"Postoperative ketoacidosis with hypoglycemia in a nondiabetic patient taking dapagliflozin for heart failure: a case report.","volume":"16","author":"Seki","year":"2022","journal-title":"A A Pract"},{"issue":"1","key":"soi250016r27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jemermed.2017.10.001","article-title":"Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a case report.","volume":"54","author":"Brown","year":"2018","journal-title":"J Emerg Med"},{"issue":"2","key":"soi250016r28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1213\/XAA.0000000000000734","article-title":"When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium-glucose cotransporter-2 inhibitor: a case report.","volume":"11","author":"Lane","year":"2018","journal-title":"A A Pract"},{"issue":"1","key":"soi250016r29","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.soard.2015.08.502","article-title":"Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin.","volume":"12","author":"Bonanni","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"soi250016r30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.dsx.2021.04.016","article-title":"Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery.","volume":"15","author":"Kuchay","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"soi250016r31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1941874419835035","article-title":"Postoperative euglycemic diabetic ketoacidosis and encephalopathy related to SGLT-2 inhibitors: a case report and discussion of diabetes treatment and \u201csweet pee encephalopathy\u201d in perioperative hospital management.","volume":"10","author":"Mackintosh","year":"2020","journal-title":"Neurohospitalist"},{"issue":"1","key":"soi250016r32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.aace.2020.11.014","article-title":"A case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery.","volume":"7","author":"Osafehinti","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"3","key":"soi250016r33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? plausible role for altered glomerular hemodynamics and medullary hypoxia.","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf"},{"issue":"3","key":"soi250016r34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/anae.14569","article-title":"A review of ASA physical status\u2014historical perspectives and modern developments.","volume":"74","author":"Mayhew","year":"2019","journal-title":"Anaesthesia"},{"key":"soi250016r36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis.","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"4S","key":"soi250016r37","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"soi250016r38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40264-022-01247-3","article-title":"A population-based study of SGLT2 inhibitor-associated postoperative diabetic ketoacidosis in patients with type 2 diabetes.","volume":"46","author":"Lui","year":"2023","journal-title":"Drug Saf"},{"issue":"6","key":"soi250016r39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.jvca.2023.01.041","article-title":"Postcardiac surgery euglycemic diabetic ketoacidosis in patients on sodium-glucose cotransporter 2 inhibitors.","volume":"37","author":"Auerbach","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"6","key":"soi250016r40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis.","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"issue":"2","key":"soi250016r41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/ALN.0000000000004746","article-title":"Meaning and management of perioperative oliguria.","volume":"140","author":"Tallarico","year":"2024","journal-title":"Anesthesiology"},{"issue":"4","key":"soi250016r42","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1097\/SLA.0000000000005774","article-title":"Intraoperative use of albumin in major noncardiac surgery: incidence, variability, and association with outcomes.","volume":"278","author":"Lazzareschi","year":"2023","journal-title":"Ann Surg"},{"issue":"3","key":"soi250016r43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bja.2022.05.002","article-title":"Fluids, vasopressors, and acute kidney injury after major abdominal surgery between 2015 and 2019: a multicentre retrospective analysis.","volume":"129","author":"Chiu","year":"2022","journal-title":"Br J Anaesth"},{"issue":"23","key":"soi250016r44","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1056\/NEJMra1916393","article-title":"Cardiovascular consequences of acute kidney injury.","volume":"382","author":"Legrand","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"soi250016r45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000476077","article-title":"A role of remote organs effect in acute kidney injury outcome.","volume":"137","author":"D\u00e9pret","year":"2017","journal-title":"Nephron"},{"key":"soi250016r35","volume-title":"International Statistical Classification of Diseases, Tenth Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"soi250016r25","doi-asserted-by":"crossref","unstructured":"van Niekerk? C, Wallace? J, Takata? M, Yu? R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin. BMJ Case Rep. Published online August 20, 2018. doi:10.1136\/bcr-2017-221527","DOI":"10.1136\/bcr-2017-221527"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2833369\/jamasurgery_tallarico_2025_oi_250016_1749251633.96849.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:00:54Z","timestamp":1749654054000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2833369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2025.0940","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}